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The development of genetic engineering has enabled the 
modification of stem cells and somatic cells. T cells exert 
immune responses against cancer cells. Efforts to redirect T 
cell specificity of a chimeric antigen receptor (CAR) to a 
desired antigen began in the 1990s (Gross et al., 1989; Ku-
wana et al., 1987). In 2006, the first clinical trial using car-
bonic anhydrase IX CAR-T cells to fight renal cancer was 
conducted (Lamers et al., 2006). Until 2011, Porter et al. 
exploited CD19 CAR-T to treat refractory/relapsed chronic 
lymphoid leukemia (Porter et al., 2011). Subsequently, trials 
using CD19 CAR-T to treat hematological malignancies, 
including acute lymphoid leukemia (Grupp et al., 2013), 
lymphoma (Brentjens et al., 2013; Lee et al., 2015), and 
even multiple myeloma (Garfall et al., 2015) revealed a 
positive response rate. In 2013, along with antibodies tar-
geting immune checkpoints, CAR-T therapy reached a sci-
entific breakthrough. A 93% complete response rate of 
CD19 CAR-T based cancer immunotherapy for acute lym-
phoid leukemia was reported at the most recent American 
Society of Hematology (ASH) meeting. Currently, more 
than 70 clinical trials are recruiting patients for CAR-T- 
based cancer immunotherapy.  
In China, CAR redirected T cells have been widely in-
vestigated (Wang et al., 2009; Wang et al., 2013). Several 
antigens recognized by CAR-T cells have been exclusively 
studied in China (Deng et al., 2015; Tang et al., 2014). Gao 
et al. completed preclinical studies of using glypi-
can-3-specific CAR-T cells to treat hepatocellular carcino-
ma (Gao et al., 2014); these clinical trials are currently in 
the recruitment stage. Han et al. registered the first CD138 
CAR-T therapy for multiple myeloma (NCT01886976). 
Recent results from clinical trials in China showed substan-
tial efficacy for treating hematological malignancies (Dai et 
al., 2015; Zhang et al., 2015; Zhang et al., 2016). To date, 
29 clinical trials to evaluate the safety and efficacy of 
CAR-T therapy are being conducted in China and are ex-
pected to provide support for the safety and efficacy of 
CAR-T cells for further applications. 
It is my great honor to guest-edit this special topic fo-
cused on CAR-T in Science China Life Science. In this is-
sue, I present my understanding of the current status of 
CAR-T therapy in China and worldwide. To expand the 
therapeutic benefit for cancer patients in China, three as-
pects of CAR-T therapy must be addressed: (i) Regulatory 
guidelines specific for CAR-T therapy must be established 
to facilitate the commercialization of this cancer immuno-
therapy by pharmaceutical companies. (ii) Enhancing the 
therapeutic efficacy of CAR-T therapy for solid tumors is 
an important task. (iii) Enhancing the efficacy and safety of 
CAR-T therapy and searching for antigens specific to tumor 
cells is suggested, particularly using genome-wide se-
quencing to identify unique mutations related neo-antigens 
for CAR design. Once these aspects are resolved, 
CAR-T-based cancer immunotherapy is expected to provide 
multiple benefits to cancer patients.  
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